New 1,4-anthracene-9,10-dione derivatives as potential anticancer agents

Farmaco

Volumn 55, Issue 1, 2000, Pages 1-5

  Zagotto, G ^a   Supino, R ^b   Favini, E ^b   Moro, S ^a   Palumbo, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anthracene 9,10 dione; DNA; Molecular modeling; Specificity; Topoisomerase

Indexed keywords

ANTHRACENE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; DNA SEQUENCE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; STRUCTURE ACTIVITY RELATION;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; TUMOR CELLS, CULTURED;

EID: 0034057784     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(99)00091-9     Document Type: Article

References (24)

1. Bailly C., Chaires J.B. Sequence-specific DNA minor groove binders. Design and synthesis of netropsin and distamycin analogues. Bioconj. Chem. 9:1998;513-538.
2. Capranico G., Binaschi M. DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim. Biophys. Acta Gene Struct. Expr. 1400:1998;185-194.
3. Choi I.Y., Chung I.K., Muller M.T. Eukaryotic topoisomerase II cleavage is independent of duplex DNA conformation. Biochim. Biophys. Acta. 1264:1995;209-214.
4. Jacoby D.B., Wensink P.C. DNA binding specificities of YPF1, a Drosophila homolog to the DNA binding subunit of human DNA-dependent protein kinase, Ku. J. Biol. Chem. 271:1996;16827-16832.
5. Palumbo M. Introduction to DNA sequence-specific agents. Palumbo M. Advances in DNA Sequence Specific Agents. 3:1998;1-6 JAI Press, Greenwich, CT.
6. Lilley D.M. DNA-protein structural interactions. Lilley D.M. Frontiers in Molecular Biology. 1995;Oxford University Press, New York.
7. Gatto B., Zagotto G., Sissi C., Cera C., Uriarte E., Palu G., Capranico G., Palumbo M. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. J. Med. Chem. 39:1996;3114-3122.
8. Zagotto G., Mitaritonna G., Sissi C., Palumbo M. New peptidyl-anthraquinones: synthesis and DNA binding. Nucleosides Nucleotides. 17:1998;2135-2141.
9. Rinaldi P., Wilk M. Use of liquid crystal induced circular dichroism for absolute configurational assignments of beta-amino alcohols. J. Org. Chem. 48:1983;2141-2146.
10. Asano Y., Yamada A., Kato Y., Yamaguchi K., Hibino Y., Hirai K., Kondo K. Enantioselective synthesis of (S)-amino acids by phenylalanine dehydrogenase from Bacillus sphaericus: use of natural and recombinant enzymes. J. Org. Chem. 55:1990;5567-5571.
11. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112.
12. Molecular Operating Environment (MOE 1998.10), Chemical Computing Group Inc., 1255 University St, Suite 1600, Montreal, Quebec, Canada, H3B 3X3, 1998.
13. Halgren T.A. Merck molecular force field 1. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 17:1996;490-519.
14. Halgren T.A. Merck molecular force field 2. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J. Comput. Chem. 17:1996;520-552.
15. Halgren T.A. Merck molecular force field 3. Molecular geometries and vibrational frequencies for MMFF94. J. Comput. Chem. 17:1996;553-586.
16. Halgren T.A., Nachbar R.B. Merck molecular force field 4. Conformational energies and geometries for MMFF94. J. Comput. Chem. 17:1996;587-615.
17. Halgren T.A. Merck molecular force field 5. Extension of MMFF94 using experimental data, additional computational data, and empirical rules. J. Comput. Chem. 17:1996;616-641.
18. M.J. Frisch, Gaussian Inc., Pittsburg PA, 1988.
19. Bayer O. Chinone. Houben J., Weyl T. Methoden der Organischen Chemie. VII/3C:1979;Georg Thieme Verlag, Stuttgart.
20. Cummings J., Meikle I., Macpherson J.S., Smyth J.F. Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505. Anti Cancer Drug Des. 11:1996;367-382.
21. Cummings J., Meikle I., Macpherson J.S, Smyth J.F. Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography. J. Chromatogr. B. 685:1996;159-164.
22. Meikle I., Cummings J., Macpherson J.S., Smyth J.F. Induction of apoptosis in human cancer cell lines by the novel anthracenyl amino acid topoisomerase I inhibitor NU/ICRF 505. Br. J. Cancer. 74:1996;374-379.
23. Meikle I., Cummings J., Macpherson J.S., Smyth J.F. Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance. Biochem. Pharmacol. 52:1996;979-990.
24. Meikle I., Cummings J., Macpherson J.S., Smyth J.F. Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs. Anti Cancer Drug Des. 10:1995;515-527.